Thaçi D 1 , Sidhu M 2 , Dorsch B 3 , Köhne-Volland R 3 , Ehlken B 4 , Berger K 4 1 University Hospital of J W Goethe University, Frankfurt, Germany, 2 Astellas Pharma Europe Ltd, Staines, Middlesex, UK, 3 Metronomia Clinical Research GmbH, München, Germany, 4 IMS Health, Munich, Germany OBJECTIVE: To describe treatment outcomes and to evaluate resource utilization and associated cost of proactive use of tacrolimus ointment (PU) versus standard use of tacrolimus ointment (SU) in children with moderate or severe atopic dermatitis (AD) over a period of 12 months. METHODS: A pan-European, phase III multicentre randomized clinical trial FG-506-06-41 'CONTROL' was conducted. After randomization patients (2-15 years old) applied tacrolimus 0.03% ointment (PU) or vehicle ointment (SU) at the usually affected areas twice per week for 12 months. Disease exacerbations were treated using open-label tacrolimus 0.03% ointment twice daily. Resource utilization data (e.g. for ointments, drugs, doctor consultations, out-of-pocketexpenses, absence from school) were collected alongside the clinical trial by caregiver questionnaires, prospectively. Costs of pooled resource data were determined using German unit cost data. Direct and indirect costs were considered from third party payer (TPP), caregiver, and societal perspectives. RESULTS: 146 patients were included in the analysis, 75 PU patients (53% moderately affected) and 71 SU patients (51% moderately affected). Mean age of patients was 7 years (SD 3.9/4.5) in both treatment groups. Mean + SD body surface area in both groups was 1.0 + 0.4 m2. The mean number of disease exacerbations requiring substantial therapeutic intervention in the PU and SU arms was 1.7 + 2.2 and 3.4 + 3.2 (p < 0.001), respectively. In patients with severe AD the mean total annual cost per patient was higher in the standard regimen €2,002 + 2,315 compared to PU €1,571 + 1,122. In the subgroup of severely affected 2-6 year-old patients these cost differences were larger in favour of tacrolimus ointment: €1,465 + 837 (PU) versus €2,253 + 2,855 (SU). In moderately affected patients there were no cost differences: €1,233 + 1,507 (PU) and €1,136 + 1,494 (SU). CONCLU-SION: Proactive treatment with tacrolimus 0.03% ointment is more effective and leads to cost savings in comparison to standard treatment with tacrolimus 0.03% ointment, especially in children with severe AD.
PSS24 TRENDS IN EPISODE OF TREATMENT COSTS OF ACNE ACROSS THE UNITED STATES
Balkrishnan R 1 , Uhas AA 2 , Feldman SR 3 1 The Ohio State University, Columbus, OH, USA, 2 The Ohio State University College of Pharmacy, Columbus, OH, USA, 3 Wake Forest University School of Medicine, Winston Salem, NC, USA OBJECTIVE: Acne is a common dermatological condition and impacts millions of adolescent and adult lives in the United States (US). The purpose of this study was to accurately quantify the cost per episode for the treatment of acne in the US and to examine disparities in treatment costs. METHODS: Information was collected from the PharMetrics Integrated Patient-centric Database, a large collection of administrative claims in the year 2004. The database included more than 80 public and private health care plans included in the database, representing approximately 9.6 million unique patients. Analysis was performed using the Total Resource Utilization (TRU) Benchmarks process, a descriptive methodology which organizes and separates information from the third-party database, into accessible benchmarks for comparison. RESULTS: There are many different drug treatment therapies that can be used to treat acne which can range in price dramatically. The average acne episode cost $777.19, with pharmacy costs representing 59.5% and outpatient costs representing 39.1%. Inpatient services were reported in only 0.1% of acne episodes and were associated with $9,297.56 in costs. For patients diagnosed with acne, pharmacy visits represented 85.5% of all episodes. Average outpatient costs were $303.99, attributable to 3.73 outpatient services with 2.18 of these services were physician visits. The lowest average total episode costs were found in the South-central region and were $624.05. The highest Abstracts A291 average total episode costs were found in the Northeast region and were $856.50. Average outpatient costs in the Northeast region were the highest in the country at $377.64-the range for other regions was $240. To determine the most cost-effective Wet AMD treatment alternative in Mexico. METHODS: A decision tree with Bayesian approach and a Markov chain considering the probabilities of increasing, decreasing or maintaining visual acuity (VA) through eight health states based on VA from 20/20 to 20/400 due to the use of a pharmacological alternative, with a time horizon of 5 years and institutional perspective, were performed. The discounting rate was three percent for costs and benefits. Adverse events and their treatment costs, for every alternative were considered; costs, benefits and probabilities of transition data were estimated from the meta-analysis with available published literature, including the MARINA and ANCHOR studies, validated by a panel of Mexican experts through the Delphi technique. Study comparators examined were Ranibizumab (RAN), photodynamic therapy with Verteporfin (PDTV), pegaptanib sodium (PEG) and standard care (STD). Sensitivity analysis was one-way and probabilistic (acceptability curve, analysis of components for the ellipse method). RESULTS: Patients using Ranibizumab get more benefits (RAN = 2.71 QALY; PDTV = 2.03 QALY; PEG = 1.89 QALY; STD = 1.78 QALY), with the lowest total cost per treatment (RAN = $43,984 USD; STD = $63,531 USD; PDTV = $83,546 USD; PEG = $92,247 USD) and the lowest cost per QALY (RAN = $16,257 USD/QALY; STD = $35,749 USD/QALY; PDTV = $41,074 USD/QALY; PEG = $48,263 USD/QALY). Incremental analysis showed Ranibizumab to be the dominant alternative. Net benefits are greater with Ranibizumab independent of willingness to pay. Acceptability curves showed absolute superiority for Ranibizumab. The confidence interval of 95% with the ellipse method showed Ranibizumab to be dominant in 95% of the cases with a willingness to pay of $924USD. The sensitivity analysis on efficiency and costs of Ranibizumab in an interval of Ϯ50%, was robust with the base analysis. CONCLUSION: Ranibizumab is the most cost-effective Wet AMD treatment alternative; it offers the greatest benefits with the lowest cost. Sensitivity analyses showed the robustness of the base study.
PSS26 USING COST-UTILITY ANALYSIS TO ASSESS THE BUDGET IMPACT OF BIOLOGICS FOR THE TREATMENT OF PSORIASIS (PSO)
Spiegel BM 1 , Patel V 2 , Chiou CF 2 , Esrailian E 1 1 VA Greater Los Angeles Healthcare System; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 2 Amgen Inc, Thousand Oaks, CA, USA OBJECTIVE: Measure incremental cost-utility and budget impact of etanercept vs. infliximab in moderate-to-severe PSO with >10% body surface area involvement. METHODS: We used a Markov decision analysis to compare 2 strategies for PSO: etanercept label dose (50 mg BIW x12 wks, then 25 mg BIW); and infliximab label dose (5 mg/kg IV at wks 0, 2, and 6, then 5mg/kg Q8W). We derived 60 probability estimates through systematic review of the literature and labels, varying each of these estimates in each sensitivity analysis. We adopted an MCO payer's perspective, and included cost estimates for a comprehensive list of related resources as determined by Medicare and the Red Book. Qulaity-adjusted life-years (QALYs) were estimated by applying utilities from the literature to reported efficacy as measured by PASI scores. We calculated the incremental cost per QALY gained and incremental per-member per month (PMPM) budget impact in a hypothetical MCO of 1 million lives (assuming a 1% prevalence of moderate-to-severe PSO First year persistence measures: whether last fill had sufficient days supply to achieve medication possession at year's end; number of days for which index agent was available (days covered). Possible inconsistencies between quantity dispensed and reported days supply addressed by multiplying claimed days supply with alternative measures from the literature. Models of associations between index agent and medication possession (logistic regression) and days covered (linear regression) were adjusted for gender, age, and previous ocular hypertension diagnosis. RESULTS: A total of 7783 patients met inclusion criteria (LAT, n = 4994; BIM, n = 1464; TRAV, n = 1415). Overall medi-
